First Time Loading...

Pfizer Inc
NYSE:PFE

Watchlist Manager
Pfizer Inc Logo
Pfizer Inc
NYSE:PFE
Watchlist
Price: 26.56 USD -1.78% Market Closed
Updated: Mar 1, 2024

Intrinsic Value

Pfizer Inc. is a research-based global biopharmaceutical company. [ Read More ]

The intrinsic value of one PFE stock under the Base Case scenario is 27.07 USD. Compared to the current market price of 26.56 USD, Pfizer Inc is Undervalued by 2%.

Key Points:
PFE Intrinsic Value
Base Case
27.07 USD
Undervaluation 2%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Pfizer Inc

Backtest PFE Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling PFE stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Substantial Revenue Growth Despite COVID Product Dip
2023-Q4 Earnings Call

Substantial Revenue Growth Despite COVID Product Dip

In the midst of evolving market conditions and strategic pivots, the company maintained a 7% operational revenue growth, reporting $58.5 billion excluding COMIRNATY and PAXLOVID. The dramatic sales decline in COVID products, with a 41% operational decrease and a $3.5 billion revenue reversal, signaled a shift from pandemic-driven demand. Despite this, newly approved vaccines and blockbusters like VYNDAQEL and Eliquis contributed to an 8% year-over-year growth when setting COVID products aside. The company aligns future expectations with investments in commercial and manufacturing capabilities to propel its portfolio, particularly the Seagen acquisition's anticipated $120 million contribution. With an adjusted EPS forecast of $2.05 to $2.25 for 2024, inclusive of a $0.40 dilution from Seagen, they aim for an operational revenue increase of 8% to 10%, confident in $4 billion cost savings from realignment and eyeing long-term shareholder value.

Financials

Balance Sheet Decomposition
Pfizer Inc

Current Assets 74B
Cash & Short-Term Investments 44.2B
Receivables 15B
Other Current Assets 14.8B
Non-Current Assets 141B
Long-Term Investments 14.2B
PP&E 17.9B
Intangibles 91.8B
Other Non-Current Assets 17.2B
Current Liabilities 31.1B
Accounts Payable 5.3B
Accrued Liabilities 2.4B
Short-Term Debt 298m
Other Current Liabilities 23.1B
Non-Current Liabilities 87B
Long-Term Debt 61B
Other Non-Current Liabilities 25.9B
Efficiency
Fundamental Scores

PFE Profitability Score
Profitability Due Diligence

Pfizer Inc's profitability score is 64/100. The higher the profitability score, the more profitable the company is.

Positive Free Cash Flow
Positive Gross Profit
Positive 3-Year Average ROE
Positive Operating Income
64/100
Profitability
Score

Pfizer Inc's profitability score is 64/100. The higher the profitability score, the more profitable the company is.

PFE Solvency Score
Solvency Due Diligence

Pfizer Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Positive Net Debt
54/100
Solvency
Score

Pfizer Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PFE Price Targets Summary
Pfizer Inc

Wall Street analysts forecast PFE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PFE is 32.96 USD with a low forecast of 26.26 USD and a high forecast of 52.5 USD.

Lowest
Price Target
26.26 USD
1% Downside
Average
Price Target
32.96 USD
24% Upside
Highest
Price Target
52.5 USD
98% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

PFE Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

PFE Price
Pfizer Inc

1M 1M
-3%
6M 6M
-26%
1Y 1Y
-33%
3Y 3Y
-15%
5Y 5Y
-24%
10Y 10Y
+23%
Annual Price Range
26.56
52w Low
26.13
52w High
41.34
Price Metrics
Average Annual Return 12.38%
Standard Deviation of Annual Returns 32.08%
Max Drawdown -55%
Shares Statistics
Market Capitalization 150B USD
Shares Outstanding 5 646 779 904
Percentage of Shares Shorted 1.07%

PFE Return Decomposition
Main factors of price return

What is price return decomposition?

PFE News

Other Videos

Last Important Events
Pfizer Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Pfizer Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Pfizer Inc Logo
Pfizer Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

150B USD

Dividend Yield

6.29%

Description

Pfizer Inc. is a research-based global biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 79,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products. Its global portfolio includes medicines and vaccines. The firm offers therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator in development for a range of immuno-inflammatory diseases, including ulcerative colitis, Crohn’s Disease, atopic dermatitis, eosinophilic esophagitis, and alopecia areata. The firm works across markets to develop wellness, prevention, treatments and cures. The company collaborates with healthcare providers, governments and local communities to support and provide access to healthcare. The firm's medicines and vaccines provide value for healthcare providers and patients, through treatment of diseases, improvements in health, wellness.

Contact

NEW YORK
New York City
235 E 42nd St
+12125732323.0
https://www.pfizer.com/

IPO

1944-01-17

Employees

79 000

Officers

Chairman of the Board & CEO
Dr. Albert Bourla D.V.M., Ph.D.
Chief Financial Officer & Executive VP
Mr. David M. Denton
Chief Scientific Officer and President of Research & Development
Dr. Mikael Dolsten M.D., Ph.D.
Senior VP, Controller & Principal Accounting Officer
Ms. Jennifer B. Damico
Executive VP and Chief Digital & Technology Officer
Ms. Lidia L. Fonseca
Chief Investor Relations Officer
Ms. Francesca M. DeMartino
Show More
Executive VP & General Counsel
Mr. Douglas M. Lankler
Executive VP and Chief Compliance, Quality & Risk Officer
Mr. Rady A. Johnson
Global Chief Marketing Officer
Mr. Andreas J. Panayiotou
Chief People Experience Officer & Executive VP
Ms. Payal Sahni Becher
Show Less

See Also

Discover More
What is the Intrinsic Value of one PFE stock?

The intrinsic value of one PFE stock under the Base Case scenario is 27.07 USD.

Is PFE stock undervalued or overvalued?

Compared to the current market price of 26.56 USD, Pfizer Inc is Undervalued by 2%.